{
    "nctId": "NCT03374995",
    "briefTitle": "Topical Keratin in Treating Radiation Dermatitis in Patients With Breast Cancer",
    "officialTitle": "Pilot Study: KeraStat Cream for Radiation Dermatitis",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Carcinoma, Radiation-Induced Dermatitis",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 25,
    "primaryOutcomeMeasure": "Incidence of Early Adverse Skin Reactions (EASRs)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of breast cancer, received chemotherapy, and scheduled to receive 4 to 6 weeks of radiation therapy (radiation protocol of 42 Gy+)\n* Area to be irradiated representing 1-10% of total body surface area (TBSA)\n* Able and willing to sign protocol consent form\n* Able and willing to document symptoms and treatment details as often as needed, not to exceed daily notes\n* Able and willing to have photographs of the affected area taken regularly\n\nExclusion Criteria:\n\n* Women who are pregnant, lactating/nursing or plan to become pregnant\n* Previous radiation therapy to the area to be treated with radiation therapy\n* Receiving palliative radiation therapy\n* Unhealed or infected surgical sites in the irradiation area\n* Patients undergoing cytotoxic chemotherapy or concurrent Herceptin as part of overall treatment plan (tamoxifen/aromatase inhibitor allowed)\n* Use of oral corticosteroids or topical corticosteroids in the irradiation area\n* Use of Erbitux\n* Autoimmune disease\n* Skin disease in target irradiation area\n* Smoker\n* Known allergy to the standard of care or ingredients in KeraStat Cream",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}